Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Dicerna Pharmaceuticals stock | $32.6
Learn how to easily invest in Dicerna Pharmaceuticals stock.
Dicerna Pharmaceuticals, Inc is a biotechnology business based in the US. Dicerna Pharmaceuticals shares (DRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Dicerna Pharmaceuticals employs 302 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Dicerna Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – DRNA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Dicerna Pharmaceuticals stock price (NASDAQ: DRNA)Use our graph to track the performance of DRNA stocks over time.
Dicerna Pharmaceuticals shares at a glance
|Latest market close||$32.60|
|52-week range||$16.50 - $40.14|
|50-day moving average||$37.34|
|200-day moving average||$29.69|
|Wall St. target price||$42.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.38|
Buy Dicerna Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Dicerna Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Dicerna Pharmaceuticals price performance over time
|1 week (2021-07-23)||N/A|
|1 month (2021-07-02)||-13.69%|
|3 months (2021-05-03)||7.63%|
|6 months (2021-01-30)||N/A|
|1 year (2020-07-30)||N/A|
|2 years (2019-07-30)||N/A|
|3 years (2018-07-30)||N/A|
|5 years (2016-07-30)||N/A|
Dicerna Pharmaceuticals financials
|Revenue TTM||$177.9 million|
|Gross profit TTM||$-41,077,000|
|Return on assets TTM||-10.02%|
|Return on equity TTM||-79.01%|
|Market capitalisation||$2.9 billion|
TTM: trailing 12 months
Shorting Dicerna Pharmaceuticals shares
There are currently 4.8 million Dicerna Pharmaceuticals shares held short by investors – that's known as Dicerna Pharmaceuticals's "short interest". This figure is 19% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting Dicerna Pharmaceuticals shares can be evaluated.
Dicerna Pharmaceuticals's "short interest ratio" (SIR)
Dicerna Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Dicerna Pharmaceuticals shares currently shorted divided by the average quantity of Dicerna Pharmaceuticals shares traded daily (recently around 769217.31391586). Dicerna Pharmaceuticals's SIR currently stands at 6.18. In other words for every 100,000 Dicerna Pharmaceuticals shares traded daily on the market, roughly 6180 shares are currently held short.
However Dicerna Pharmaceuticals's short interest can also be evaluated against the total number of Dicerna Pharmaceuticals shares, or, against the total number of tradable Dicerna Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dicerna Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Dicerna Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0745% of the tradable shares (for every 100,000 tradable Dicerna Pharmaceuticals shares, roughly 75 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dicerna Pharmaceuticals.
Find out more about how you can short Dicerna Pharmaceuticals stock.
Dicerna Pharmaceuticals share dividends
We're not expecting Dicerna Pharmaceuticals to pay a dividend over the next 12 months.
Dicerna Pharmaceuticals share price volatility
Over the last 12 months, Dicerna Pharmaceuticals's shares have ranged in value from as little as $16.5 up to $40.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dicerna Pharmaceuticals's is 1.0658. This would suggest that Dicerna Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Dicerna Pharmaceuticals overview
Dicerna Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Stocks similar to Dicerna Pharmaceuticals
Dicerna Pharmaceuticals in the news
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
Dicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growth
Frequently asked questionsWhat percentage of Dicerna Pharmaceuticals is owned by insiders or institutions?
Currently 7.239% of Dicerna Pharmaceuticals shares are held by insiders and 83.56% by institutions. How many people work for Dicerna Pharmaceuticals?
Latest data suggests 302 work at Dicerna Pharmaceuticals. When does the fiscal year end for Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals's fiscal year ends in December. Where is Dicerna Pharmaceuticals based?
Dicerna Pharmaceuticals's address is: 75 Hayden Avenue, Lexington, MA, United States, 02421 What is Dicerna Pharmaceuticals's ISIN number?
Dicerna Pharmaceuticals's international securities identification number is: US2530311081 What is Dicerna Pharmaceuticals's CUSIP number?
Dicerna Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 253031108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert